This looks like a huge deal for Amarantus- they get all of the Diagnostic assets back plus an additional 31 million shares- lol. Pretty unbelievable really. Avant is truly a shell company now so no one really there to look after things. The big question is how this impacts the current deal with the note holders. They were going to get those 80 million shares. Now Amarantus will have 110 million shares, but Avant no longer has the diagnostics so the shares are worth less). Also I wonder how long this might delay a tender exchange. Hopefully, the noteholders agree to just take the 110 million shares and everything else stays the same as it was. I wonder if this whole deal came about after Goix left- if so then it happened really quickly.
(2)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links